Neurosurgery News and Research

RSS

Misonix receives donation from anonoymous patient to buy SonicOne ultrasonic wound care system

Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.

15 Sep 2009

Mortality index can be misleading in major specialties

A key statistic that consumer groups and the media often use when compiling hospital report cards and national rankings can be misleading, researchers report in a new study.

15 Sep 2009

Genetic switch that causes excessive mucus in the lungs identified

Scientists have identified the main genetic switch that causes excessive mucus in the lungs, a discovery that one day could ease suffering for people with chronic lung diseases like asthma and cystic fibrosis, or just those fighting the common cold.

15 Sep 2009

Innovative stroke treatment device to minimize brain damage

Driven by the emergency-room maxim, "Time is brain," NeuroInterventions, Inc. is prototyping an innovative stroke treatment device designed to speed up the restoration of blood flow and thus minimize brain damage.

14 Sep 2009

Newly established Edward Neurosciences Institute to provide advanced stroke care in Chicago

Edward Hospital announced today that it has established the Edward Neurosciences Institute in affiliation with the Northwestern Medical Faculty Foundation to bring the highest level of stroke care in the world to the west and southwest suburbs of Chicago.

11 Sep 2009

Scientist awarded grant to study the role of VENs in quick decision making

A scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has been awarded a $400,000 grant from the James S. McDonnell Foundation to help study a rare cell type that is believed to play a role in quick decision making and intuition. Abnormalities in this cell type have been seen in people suffering from autism and dementia.

10 Sep 2009

Human neural stem cells to treat Pelizaeus-Merzbacher Disease

StemCells, Inc. (NASDAQ:STEM) announced today that it will soon initiate with the University of California, San Francisco (UCSF) Children’s Hospital a Phase I clinical trial to evaluate the therapeutic potential of StemCells’ proprietary HuCNS-SC® product candidate (purified human neural stem cells) to treat Pelizaeus-Merzbacher Disease (PMD), a myelination disorder that primarily affects infants and young children.

10 Sep 2009

New protocol to tackle postpartum depression

Up to 80 percent of women experience depressive symptoms postpartum, with one in eight reporting the emergence of major depression within weeks of delivery.

10 Sep 2009

St. Jude Medical's Brio neurostimulator receives CE Mark approval

St. Jude Medical, Inc. (NYSE:STJ) today announced CE (Conformité Européenne) Mark approval of the Brio™ neurostimulator, the world’s smallest, longest-lasting rechargeable deep brain stimulation (DBS) device for treating the symptoms of Parkinson’s disease. A 67-year-old man who has suffered from Parkinson’s disease for more than 26 years became the first person to be implanted with the Brio neurostimulator.

9 Sep 2009

A voluntary recall program announced by CONMED Linvatec

CONMED Corporation's (NASDAQ: CNMD) CONMED Linvatec unit announced today a voluntary recall for certain model numbers of the PRO5 & PRO6 series battery handpieces manufactured prior to May 31, 2008, and certain lots of the MC5057 Universal Cable manufactured prior to December 1, 2006 used with certain of CONMED Linvatec's electric powered handpieces.

9 Sep 2009

Misleading information in hospital report cards can impact patients’ health care

A key statistic that consumer groups and the media often use when compiling hospital report cards and national rankings can be misleading, researchers report in a new study.

9 Sep 2009

CARO and Elekta award $75,000 fellowship for lung cancer research

The Canadian Association of Radiation Oncology (CARO), along with international medical-technology group Elekta, are pleased to award the 2009 CARO-Elekta Research Fellowship to Radiation Oncologist, Dr. David Palma.

From Elekta 5 Sep 2009

Proton Therapy facility in Prague to implement Elekta's information management systems

Elekta (STO:EKTAB) will provide treatment planning and information management systems for a major Proton Therapy facility in Prague, Czech Republic. The software solutions will facilitate the highest quality of patient care and lead to improved clinical efficiency.

From Elekta 5 Sep 2009

IMRIS sells IMRISneuro to Le Bonheur Children's Medical Center

IMRIS Inc. (TSX: IM) ("IMRIS" or the "Company") today announced the sale of its flagship product, IMRISneuro, to Le Bonheur Children's Medical Center.

4 Sep 2009

Top cancer hospitals have Elekta solutions for information management

Banner Good Samaritan treats cancers and neurological disorders with the Novalis Tx radiosurgery platform

John J. Kresl, M.D., Ph.D., and colleagues at Banner Good Samaritan Medical Center are now treating a wide variety of cancers and neurological disorders with highly-accurate, non-invasive, image-guided radiosurgery using the Novalis Tx(TM) radiosurgery platform from Varian Medical Systems (NYSE: VAR) and BrainLAB.

4 Sep 2009

New treatment for vaso-occlusive crisis in sickle cell patients

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children’s Hospital & Research Center Oakland in California.

4 Sep 2009

Optimized turmeric extracts may prevent memory loss

scientists with HerbalScience Group LLC, working with researchers from other organizations and medical institutions, conducted an in-depth study of optimized turmeric extracts, demonstrating that key bioactives in the botanical extracts inhibit aggregation and release of amyloid, a protein fragment considered a prime causal suspect in Alzheimer's disease.

3 Sep 2009

Elekta Holdings appoints new CEO

James Hoey has been named CEO of Elekta Holdings with overall responsibility for all of Elekta’s North American legal entities. He will also assume responsibility for Region North America, replacing Joseph Jachinowski who has decided to leave the company for an external position.

From Elekta 3 Sep 2009

Interim Phase II data of Cotara reveals signs of efficacy in GBM patients

Peregrine Pharmaceuticals, Inc. today reported that clinical investigators are presenting interim Phase II data showing that its brain cancer agent Cotara(R) appeared well tolerated and demonstrated encouraging signs of efficacy in patients with glioblastoma multiforme (GBM), the deadliest form of brain cancer.

3 Sep 2009